This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Glucagon-like peptide-1 receptor (GLP1R; GLP-1R)	<p>Studies in mice suggest that GLP-1R agonists could be useful for treating AD. In a mouse model of AD, the GLP-1R agonist Victoza liraglutide increased cognitive performance and decreased β-amyloid ($A\beta$) pathology compared with saline. Next steps include clinical testing of Victoza to treat AD.</p> <p>Novo Nordisk A/S markets Victoza to treat type 2 diabetes.</p> <p>At least 19 other companies have GLP-1R agonists in stages ranging from preclinical to marketed for endocrine, cardiovascular and gastrointestinal diseases.</p> <p>SciBX 4(19); doi:10.1038/scibx.2011.547 Published online May 12, 2011</p>	Patent pending; available for licensing	<p>McClean, P.L. <i>et al. J. Neurosci.</i>; published online April 27, 2011; doi:10.1523/JNEUROSCI.0529-11.2011</p> <p>Contact: Christian Hölscher, University of Ulster, Coleraine, Ireland e-mail: c.holscher@ulster.ac.uk</p>